Biotek-snakken — Februar 2025
-
Her et link til interviewet: https://www.youtube.com/live/Df_VE2nly5Q
-
Infant Bacterial Therapeutics AB (publ) Year-end report January 1 – December 31, 2024
"I ett optimistiskt tänkbart scenario skulle läkemedelskandidaten IBP-9414 kunna erhålla ett godkännande i USA redan under innevarande år, uppger IBT:s vd Staffan Strömberg i bokslutsrapporten"
-
Infant Bacterial Therapeutics AB (publ)
Year-end report January 1 – December 31, 2024https://storage.mfn.se/9bfcfa45-2672-4224-99c4-1edb07dff675/ibt-year-end-report-2024-eng.pdf
-
Genovis kommer med Q4 2024 i morgen kl. 8:00.
-
Hej nogen der er med på denne her Moleculin Biotech (MBRX )og som ved hvad der sker nede 60% den sidste uge ?
så skete der noget oppe med 230 % på en FDA fast trak dejligt med mine suppleringer af mange gange på 0,42-0,57-0,69 så er snart i plus og har mange som i rigtig mange
-
IRLAB Q4: Upcoming Pirepemat readout in focus
(Redeye Research Update 2025-02-13)
-
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History - Yahoo Finance
Find the latest Moleculin Biotech, Inc. (MBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Yahoo Finance (finance.yahoo.com)
-
exitnu ja er godt med på hvad der sker nu dejligt har fået solgt 3400 stk. og er stadig godt lastet med casen dejligt med mine supplerings køb de sidste dage på 0,42-0,57- og 0,69 fik købt 5000 ekstra op så super dejligt at ramme bare en gang i mellem (det hjælper dog ikke meget på det tab på stort 6 cifret beløb på Xbrane og ligeledes på Hansa og så mange andre Hmm... the show must go on god aften til dig
-
Genovis Year-end report January – December 2024
-
-
"Despite the financials falling short of our estimates (with relatively minor deviations in absolute figures), we expect the share to trade in positive territory following the quarterly report, it is currently trading slightly above our bear case. We believe the market will start recognizing the improving end market and acknowledge that 2025 is well-positioned for continued growth with expanding profitability in Genovis' enzyme business."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind